5-AZACITIDINE MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK AML AND MDS

被引：0
|
作者：
Puglisi, Bruna
Saraceni, Francesco
Guerzoni, Selene
Scortechini, Ilaria
Mancini, Giorgia
Fiorentini, Alessandro
Lotito, Antonio
Colaneri, Francesca Romana
Federici, Irene
Olivieri, Attilio
机构：
来源：
BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / SUPP1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P307
引用
收藏
页码：364 / 365
页数：2
相关论文
共 50 条
  • [31] SIRPB1: BIOMARKER OF RESPONSE TO 5-AZACITIDINE TREATMENT IN MDS AND AML PATIENTS
    Guadagnuolo, V.
    Papayannidis, C.
    Iacobucci, I.
    Fontana, M. C.
    Simonetti, G.
    Padella, A.
    Imbrogno, E.
    Paolini, S.
    Abbenante, M. C.
    Parisi, S.
    Sartor, C.
    Ottaviani, E.
    Ferrari, A.
    Delledonne, M.
    Malagola, M.
    Fili, C.
    Russo, D.
    Cavo, M.
    Martinelli, G.
    HAEMATOLOGICA, 2015, 100 : 479 - 480
  • [32] SIRPB1: BIOMARKER OF RESPONSE TO 5-AZACITIDINE TREATMENT IN MDS AND AML PATIENTS
    Guadagnuolo, V.
    Fontana, M. C.
    Papayannidis, C.
    Iacobucci, I.
    Padella, A.
    Simonetti, G.
    Imbrogno, E.
    Paolini, S.
    Abbenante, M.
    Parisi, S.
    Sartor, C.
    Ottaviani, E.
    Ferrari, A.
    Delledonne, M.
    Malagola, M.
    Fili, C.
    Russo, D.
    Cavo, M.
    Martinelli, G.
    HAEMATOLOGICA, 2015, 100 : 53 - 53
  • [33] In vivo effect of 5-azacitidine treatment in regulatory T cells in patients with AML/MDS
    Buenasmananas, D.
    Serrano-Lopez, J.
    Serrano, J.
    Casano, J.
    Garcia-Torres, E.
    Martinez-Losada, C.
    Chic, C.
    Llamas, M. J.
    Figueroa, V.
    Sanchez-Garia, J.
    LEUKEMIA RESEARCH, 2013, 37 : S131 - S132
  • [34] The Use of 5-Azacitidine in Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience
    Martin Lopez, Ana A.
    Diez Campelo, Maria
    Rojas Porras, Silvia
    Redondo Guijo, Alba
    Lopez Corral, Lucia
    Sanchez Guijo, Fermin
    del Canizo, Consuelo
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S298 - S299
  • [35] The use of 5-azacitidine in allogeneic hematopoietic cell transplantation: A single center experience
    Diez Campelo, M.
    Martin, A. A.
    Rojas, S. M.
    Redondo, A.
    Labrador, J.
    Lopez-Corral, L.
    Sanchez-Guijo, F. M.
    Canizo, M. C.
    LEUKEMIA RESEARCH, 2013, 37 : S120 - S120
  • [36] A diffuse rash in a patient after allogeneic hematopoietic stem cell transplant for AML
    Ferdjallah, Asmaa
    Boull, Christina L.
    Stefanski, Heather
    Ebens, Christen L.
    CLINICAL CASE REPORTS, 2020, 8 (12): : 3624 - 3626
  • [37] Venetoclax Plus Azacitidine Versus Azacitidine Alone As Post-Transplant Maintenance Treatment in High-Risk AML and MDS
    Cao, Yigeng
    Guo, Wenwen
    Zhai, Weihua
    Wei, Jialin
    Ma, Qiaoling
    Yang, Donglin
    Pang, AiMing
    Han, Mingzhe
    Jiang, Erlie
    BLOOD, 2023, 142
  • [38] VENETOCLAX PLUS AZACITIDINE VERSUS AZACITIDINE ALONE AS POST-TRANSPLANT MAINTENANCE TREATMENT IN HIGH-RISK AML AND MDS
    Cao, Yigeng
    Guo, Wenwen
    Jiang, Erlie
    BONE MARROW TRANSPLANTATION, 2024, 59 : 532 - 533
  • [39] 5-AZACITIDINE TREATMENT RESTORES RESPONSE TO EPOETIN THERAPY IN HIGH RISK MYELODYSPLASTIC (MDS) PATIENTS
    Volpe, M.
    Volpe, A.
    HAEMATOLOGICA, 2012, 97 : 588 - 589
  • [40] CC-486 (Oral Azacitidine) Maintenance Therapy Is Well Tolerated after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
    de Lima, Marcos
    Oran, Betul
    Papadopoulos, Esperanza B.
    Scott, Bart L.
    William, Basem M.
    Giralt, Sergio A.
    Champlin, Richard E.
    Hetzer, Joel
    Tosolini, Alessandra
    Laille, Eric
    Skikne, Barry S.
    Craddock, Charles
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S312 - S313
12345